Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
18 Luglio 2023 - 8:06AM
Business Wire
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic disorders,
today announced its participation at the upcoming H.C. Wainwright 2nd Annual Kidney Conference, to
be held virtually on July 25, 2023.
Thomas Kuhn, CEO, and members of the management team of Poxel,
will be available for one-on-one virtual meetings on July 25, 2023.
The Company’s virtual presentation is scheduled the same day at
9:30 am ET (3.30 pm CEST) and will focus on PXL770, a novel,
first-in-class direct adenosine monophosphate-activated protein
kinase (AMPK) activator, for the treatment of autosomal dominant
polycystic kidney disease (ADPKD).
About ADPKD
Autosomal dominant polycystic kidney disease, or ADPKD, is a
form of chronic kidney disease which is mainly caused by mutations
in the PKD1 or PKD2 genes. This causes multiple cysts, (or pouches
filled with fluid), to form in the kidneys. Autosomal dominant (AD)
relates to how the disease is passed down from the parent to child.
With ADPKD, cysts develop and keep ingrown in the kidneys over
time, progressively destroying the healthy parenchyma and causing
the kidneys to increase in size and volume. Over time, the growing
cysts make it harder for the kidneys to function and eventually
lead to kidney failure. Most people with ADPKD have pain, high
blood pressure, and end up with kidney failure at some point in
their lives.
ADPKD is the fourth leading cause of chronic kidney disease
(CKD), affecting 1 in every 400 to 1,000 people (approximately
140,000 patients in the US) and is the most common kidney disorder
passed down through family members. More than 50% of ADPKD patients
develop renal failure by age 50, requiring dialysis and/or kidney
transplantation. Only one drug, tolvaptan, is approved to attenuate
progression and is associated with severe liver adverse events and
poor tolerability due to intense polyuria.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. For the treatment of
NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its
primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In
rare diseases, development of PXL770, a first-in-class
direct adenosine monophosphate-activated protein kinase (AMPK)
activator, is focused on the treatment of adrenoleukodystrophy
(ALD) and autosomal dominant polycystic kidney disease (ADPKD).
TWYMEEG® (Imeglimin), Poxel’s first-in-class product that
targets mitochondrial dysfunction, is marketed for the treatment of
type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to
receive royalties and sales-based payments. Poxel has a strategic
partnership with Sumitomo Pharma for Imeglimin in Japan, China, and
eleven other Asian countries. Listed on Euronext Paris, Poxel is
headquartered in Lyon, France, and has subsidiaries in Boston, MA,
and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717980694/en/
Investor relations / Media
Aurélie Bozza Investor Relations & Communication Senior
Director aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
NewCap Nicolas Fossiez / Arthur Rouillé poxel@newcap.eu +33 1 44
71 94 94
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Poxel (EU:POXEL)
Storico
Da Mag 2023 a Mag 2024